Drug
Nifurtimox (BAYA2502)
Nifurtimox (BAYA2502) is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
50%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution1 total trials
Phase 1Safety & dosage
1(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Completed(1)
Detailed Status
Not yet recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 11 (100.0%)
Trials by Status
not_yet_recruiting150%
completed150%
Recent Activity
0 active trials
Showing 2 of 2
not_yet_recruiting
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
NCT05477953
completedphase_1
Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients
NCT02606864
Clinical Trials (2)
Showing 2 of 2 trials
NCT05477953
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
NCT02606864Phase 1
Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2